Giredestrant vs. FulvestrantA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Sponsor:

Hoffmann-La Roche

Code:

NCT06065748

Conditions

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Giredestrant

Fulvestrant

Abemaciclib

Palbociclib

Ribociclib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-20. This information was provided to ClinicalTrials.gov by Hoffmann-La Roche on 2026-08-05.